Tyra Biosciences
TYRA
About: Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Employees: 60
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
190% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 21
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
8% more capital invested
Capital invested by funds: $500M [Q1] → $542M (+$42M) [Q2]
5.68% more ownership
Funds ownership: 100.91% [Q1] → 106.59% (+5.68%) [Q2]
3% more funds holding
Funds holding: 117 [Q1] → 121 (+4) [Q2]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 3 (-1) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
Raymond James
Chris Raymond
|
$35
|
Strong Buy
Initiated
|
3 Sep 2025 |
|
HC Wainwright & Co.
Mitchell S. Kapoor
|
$30
|
Buy
Reiterated
|
22 Aug 2025 |
|
HC Wainwright & Co.
Mitchell Kapoor
|
$30
|
Buy
Reiterated
|
1 Jul 2025 |
Financial journalist opinion
Based on 3 articles about TYRA published over the past 30 days
